Mesoblast Shares Tumble as Losses Widen (ASX:MSB)
The MSB share price down 14%. The Mesoblast [ASX:MSB] posted a FY21 net loss of $98.8 million as the FDA asks for further trials of MSB’s emergency COVID treatment…

The MSB share price down 14%. The Mesoblast [ASX:MSB] posted a FY21 net loss of $98.8 million as the FDA asks for further trials of MSB’s emergency COVID treatment…

Not every stock will go up of course, but the gold sector is also offering big cash flows. Gold is more than $2,400 an ounce for Aussie miners…that’s big margins.
By Callum Newman,

It’s only ‘crap’ if it doesn’t make you money…what tapering means for your own portfolio…well, that means small-caps then gold stocks, then what?…and more…

One of Australia’s best businessmen just summed up the current state of asset markets. Take a bow Kerry Stokes!A journo was quizzing the great man about the low interest rate policy of the central banks currently…
By Callum Newman,

You see, the science of COVID does not differ between different places. And yet, politicians manage to put in place wildly different policies.
By Nick Hubble,

The NextDC [ASX: NXT] share price fell today after the Australian data centre operator announced its full-year results for FY21.
Investment ideas from the edge of the bell curve.
Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.
All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.
The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.
Fat Tail Daily is brought to you by the team at Fat Tail Investment Research
Copyright © 2026 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988